Cited by 5,787PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAutophagy in Disease and Therapy

TOR signaling in growth and metabolism

Open access
Wullschleger, Stephan, Loewith, Robbie, Hall, Michael N.·2006·Cell

Abstract

The target of rapamycin (TOR) is a conserved Ser/Thr kinase that regulates cell growth and metabolism in response to environmental cues. Here, highlighting contributions from studies in model organisms, we review mammalian TOR complexes and the signaling branches they mediate. TOR is part of two distinct multiprotein complexes, TOR complex 1 (TORC1), which is sensitive to rapamycin, and TORC2, which is not. The physiological consequences of mammalian TORC1 dysregulation suggest that inhibitors of mammalian TOR may be useful in the treatment of cancer, cardiovascular disease, autoimmunity, and metabolic disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2006.01.016

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cellular stresses such as hypoxia or low energy status, sensed by AMPK, inhibit mTOR signaling.

    “Cellular stresses, such as hypoxia, or low energy status, which can be sensed by the AMP-sensitive kinase (AMPK) inhibit mTOR signaling”

    From Redox control of senescence and age-related disease. (2017) · cites this paper as [111]

  • Both mTOR complexes promote the transcription of genes involved in carbohydrate metabolism and lipogenesis, enhance protein translation by activating S6K, and downregulate catabolic processes through inhibiting FoxO and autophagy.

    “Both complexes promote the transcription of genes involved in carbohydrate metabolism and lipogenesis, enhance protein translation by activating ribosomal protein 6 kinase (S6K) and, at the same time, downregulate catabolic processes through inhibiting the transcriptional activity of the forkhead box transcription factors family (FoxO) and autophagy”

    From Mitochondrial Activity and Dynamics Changes Regarding Metabolism in Ageing and Obesity (2017) · cites this paper as Wullschleger et al., 2006

  • Both mTOR complexes promote transcription of genes involved in carbohydrate metabolism and lipogenesis, enhance protein translation by activating S6K, and downregulate catabolic processes through inhibiting FoxO and autophagy.

    “Both complexes promote the transcription of genes involved in carbohydrate metabolism and lipogenesis, enhance protein translation by activating ribosomal protein 6 kinase (S6K) and, at the same time, downregulate catabolic processes through inhibiting the transcriptional activity of the forkhead box transcription factors family (FoxO) and autophagy (Duvel et al., 2010; Wullschleger et al., 2006).”

    From Mitochondrial Activity and Dynamics Changes Regarding Metabolism in Ageing and Obesity (2017) · cites this paper as Wullschleger et al., 2006

  • TOR is activated in presence of abundant nutrients and inactivated under starvation.

    “For our purpose, suffice it to say that TOR is activated in the presence of abundant nutrients, and inactivated under starvation.”

    From The common biology of cancer and ageing (2007) · cites this paper as [86]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Thomas, G., Sabatini, D.M., and Hall, M.N. (2004). TOR, Target of Rapamycin (Heidelberg, Germany: Springer-Verlag).

Cited by

Sorted by citations

Authors
Wullschleger, S., Loewith, R., & Hall, M. N.
Affiliations
  • University of Basel (CH)
  • University of Geneva (CH)
Corresponding author
Hall, Michael N.
Venue
Cell
Publisher
Elsevier BV
Published
2006-02
Volume
124
Issue
3
Pages
471-484
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2134138119
Cited by
5,787
References
119
Citations by year
2026: 93 · 2025: 121 · 2024: 161 · 2023: 189 · 2022: 248 · 2021: 275 · 2020: 243 · 2019: 250 · 2018: 253 · 2017: 279 · 2016: 326 · 2015: 375 · 2014: 350 · 2013: 387 · 2012: 418
FWCI
23.80
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
TOR signaling, rapamycin, mTOR inhibitors, cell growth regulation, metabolism, Ser/Thr kinase, cancer therapy, cardiovascular disease, autoimmunity, metabolic disorders
MeSH terms
Aging, Animals, Humans, Memory, Models, Biological, Protein Kinases, Signal Transduction, Protein Serine-Threonine Kinases, Saccharomyces cerevisiae Proteins, Cell Proliferation, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review